Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Timolol 0.5% Ophthalmic Solution Clear all
Completed Phase 2 Interventional

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00287521
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

NCT02097719
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.01%, travoprost 0.004%, timolol 0.5%, hypromellose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 2, 2026, 1:36 PM EDT
Terminated Phase 1 Interventional

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

NCT01533376
View directory record Official record
Conditions
Sturge Weber Syndrome, Port-wine Mark
Interventions
Timolol, Preservative free artificial tear gel.
Drug
Lead sponsor
Wills Eye
Other
Eligibility
2 Years to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00652106
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

NCT04857827
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG)
Interventions
QLS-101, Timolol maleate PF 0.5% ophthalmic solution
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Not applicable Interventional Results available

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

NCT01257698
View directory record Official record
Conditions
Macular Hole, Retinal Detachment
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedrops
Drug
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

NCT02565173
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

NCT01915940
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Artesia, California • La Jolla, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

NCT01302249
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and IOP-Lowering Effects of WB007

NCT04149899
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions
WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 2, 2026, 1:36 PM EDT
Completed No phase listed Observational Results available

A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

NCT00823043
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
timolol hemihydrate, timolol maleate
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 2, 2026, 1:36 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07075718
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Adjunctive Study of AL-37807 Ophthalmic Suspension

NCT00620256
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT00061542
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Week to 5 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of the Bimatoprost Ocular Insert

NCT02358369
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost, Timolol 0.5%, Placebo Ocular Insert, Placebo Eye Drops
Drug · Device
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
10
States / cities
Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 2, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 2, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

NCT00465803
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Travoprost 0.004%/timolol 0.5% ophthalmic solution, Travoprost ophthalmic solution, 0.004%, Timolol maleate ophthalmic solution, 0.5%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 2, 2026, 1:36 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing

NCT07384767
View directory record Official record
Conditions
Mohs Micrographic Surgery, Excision Margin
Interventions
Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 2, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 2, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

NCT07218783
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 2, 2026, 1:36 PM EDT